B7-1 cancer vaccine

Drug Profile

B7-1 cancer vaccine

Latest Information Update: 25 Nov 2002

Price : $50

At a glance

  • Originator Kings College London; National Cancer Institute (USA); Nonindustrial sources
  • Class Cancer vaccines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Acute myeloid leukaemia; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 25 Nov 2002 No development reported - Phase-I for Acute myeloid leukaemia in United Kingdom (unspecified route)
  • 25 Nov 2002 No development reported - Phase-I for Ovarian cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top